Pulmonary drug delivery

Last updated
Illustration of the respiratory system 2301 Major Respiratory Organs.jpg
Illustration of the respiratory system

Pulmonary drug delivery is a route of administration in which patients use an inhaler to inhale their medications and drugs are absorbed into the bloodstream via the lung mucous membrane. This technique is most commonly used in the treatment of lung diseases, for example, asthma and chronic obstructive pulmonary disease (COPD). Different types of inhalers include metered-dose inhalers (MDI), dry powder inhalers (DPI), soft mist inhalers (SMI) and nebulizers. The rate and efficacy of pulmonary drug delivery are affected by drug particle properties, breathing patterns and respiratory tract geometry.

Contents

Pulmonary drug delivery minimizes systemic side effects and increases bioavailability owing to the localised absorption through the lung. The disadvantages include possible drug irritation to the lung, limited drug dissolution, relatively high drug clearance, and the drug effectiveness depends on the inhaler techniques and patients' compliance. Drug formulation can be challenging since the drug has to bypass the defence mechanisms in the respiratory tract. Pharmacokinetics and pharmacodynamics of the drug in elderly patients can also be particularly difficult to be predicted due to age-related changes in body composition.

Ongoing developments in inhaler device engineering, technology and drug formulations may improve the efficacy and overcome the challenges of pulmonary drug delivery. Recent advancements involve the utilization of the pulmonary route as an entry to systemic circulation for treating different diseases, as well as the development of pulmonary drug formulation and particle engineering technology to increase the efficacy of pulmonary delivery.


Application / Clinical use

Pulmonary drug delivery is mainly utilized for topical applications in the lungs, such as the use of inhaled beta-agonists, corticosteroids and anticholinergic agents for the treatment of asthma and COPD, the use of inhaled mucolytics and antibiotics for the treatment of cystic fibrosis (CT) and respiratory viral infections, [1] and the use of inhaled prostacyclin analogs for the treatment of pulmonary arterial hypertension (PAH). [2]

In addition, this technique is employed for systemic application, for example the use of inhaled insulin for diabetes management, [3] the use of inhaled loxapine for treatment of psychiatric disorders. Vaccines, such as the measles-rubella vaccines, can also be delivered via inhalation.

Examples of inhalers

Metered-dose inhaler Inhaler1.jpg
Metered-dose inhaler

Metered-dose inhalers (MDIs)

Metered-dose inhalers include pressurized metered-dose inhalers (pMDIs) and breath-actuated metered-dose inhalers (BAMDIs). pMDIs are the most commonly used inhalers for treating lung diseases. It requires coordination of patients’ inhalation and inhaler actuation. BAMDIs are triggered by patients’ inspiratory flow instead of hand actuation, solving the coordination issue. [4] MDIs with spacers have similar effectiveness in drug delivery compared to nebulizers, with additional benefits in convenience and cost-effectiveness. [5] The use of MDIs together with spacers, valved holding chambers (VHCs) or masks improve the efficacy of drug delivery into the lungs. [6]

Advantages

  • High portability
  • Fixed dose is delivered
  • Efficient aerosolized delivery of drug particles
  • Inexpensive
  • Convenient usage
  • Quiet administration [7]

Disadvantages

  • Require coordination between inhalation and inhaler actuation [7]

Examples

  • Pressurized metered-dose inhalers (pMDIs)
  • Breath-actuated metered-dose inhalers (BAMDIs)
Dry powder inhalers, from left to right: Turbuhaler, Accuhaler, Ellipta Dry powder inhalers.jpg
Dry powder inhalers, from left to right: Turbuhaler, Accuhaler, Ellipta

Dry powder inhalers (DPIs)

The solid drug powders in DPIs are released by the force of the patient's inspiratory flow. Turbulent airflow generated inside the inhaler by the inhalation force is associated with the movement of airflow and the resistance inside the inhaler. [8] Patients should inhale with adequate inspiratory flow to overcome the resistance of DPIs, leading to drug particle deaggregation for successful pulmonary delivery. [9]

Advantages

  • High portability
  • Fixed dose is delivered
  • Require minimal coordination between inhalation and inhaler actuation [7] [10]

Disadvantages

  • Require adequate inspiratory flow from patients
  • Moisture sensitive [7] [10]

Examples

  • Turbuhaler
  • Accuhaler
  • Handihaler
  • Genuair
  • Ellipta
  • Breexhaler
Soft-mist inhaler, Respimat Respimat.JPG
Soft-mist inhaler, Respimat

Soft-mist inhalers (SMIs)

Soft-mist inhaler aerosolized a fixed dose of liquid drug formulation into inhalable tiny particles through an extremely fine nozzle system using the energy generated by the lever-compressed spring, without the use of propellants. [11] The slow and prolonged duration of aerosolization facilitates the patient's coordination between inhaler actuation and inhalation. [12]

Advantages

  • High portability
  • Require minimal patient's coordination between inhalation and inhaler actuation
  • High drug deposition in lungs [13]

Disadvantages

  • Low availability in markets
  • Relatively expensive [10]

Example

  • Respimat

Nebulizers

Nebulizer is mainly used in emergencies, or by patients with poor compliance to other handy inhalers. Nebulizer delivers medication into the lungs by converting water-based liquid drug formulations into inhalable droplets mechanically, such as the use of an ultrasonic system, or thermally. [14] Major types of nebulizers include vibrating mesh nebulizers (VMN), jet nebulizers (JN) and ultrasonic nebulizers. [15]

Advantages

  • Patients' education and coordination are not required.
  • Suitable for older patients and children
  • Better patient satisfaction due to the visible aerosols
  • Easily employed with tidal breathing [16]

Disadvantages

  • Long time of drug delivery
  • Inaccurate drug dosages
  • Bulky device
  • Expensive
  • Require regular maintenance
  • Low drug delivery efficiency to the lungs [16]

Examples

  • Vibrating mesh nebulizers (VMN)
  • Jet nebulizers (JN)
  • Ultrasound nebulizers

Factors affecting pulmonary drug delivery

To achieve successful pulmonary drug delivery, a fraction of the inhaled particles should not deposit on the upper respiratory tract since they will be swallowed or expectorated without reaching the lungs, leading to the loss of pharmacological effect or provoking unwanted systemic side effects. Factors affecting the deposition of drug particles in lungs include drug particle properties, breathing patterns and respiratory tract geometry. [17]

Drug particle properties

Particle diameter and particle density significantly affect the drug deposition pattern in the respiratory tract, and are the most common considerations for formulation of pulmonary drugs. Drug particles with diameter larger than 5 μm, predominantly deposit on the upper respiratory tract, limiting the amount of drug particles reaching the lung. Moderate-size drug particles with diameter between 2 μm to 5 μm, primarily deposit on the central and small airways. Small drug particles with diameter smaller than 2 μm, predominantly deposit on the alveolar sacs. [18] Other factors affecting deposition of drugs include particle electrostatic charge, particle shape and particle volatility. Electrostatic charge of the drug particles enhances deposition due to the formation of electrostatic force on the wall of the respiratory tract. Non-spherical particle shape has a different entry pathway compared to that of the spherical particles, causing a change in deposition pattern. Particle volatility affects particle diameter due to the change of particle diameter during condensation and evaporation. [19]

Breathing patterns

Drug particle deposition is associated with mean residence time and tidal volume. An increase in mean residence time or tidal volume enhances drug deposition in lungs, while an increase in air flow decreases the mean residence time, resulting in the decrease of total deposition of drug particles. [20]

Respiratory tract geometry

The bifurcation of trachea into bronchi with smaller diameter increases turbulent flow, leading to an increase in deposition in the large respiratory tract by impaction. [20]

Advantages

Several advantages are associated with the pulmonary route of administration. For respiratory diseases, drug can be delivered directly to the disease site to perform topical relief, thus rapid onset of action can be achieved and there is less systemic side effects. [21] Less dosage of drug can also achieve similar therapeutic effect compared to other routes of administration. For drugs designed to exert systemic effect through the lung as a drug target, the drug can reach the circulation bypassing poor gastrointestinal absorption and hepatic first pass metabolism which improve drug bioavailability. [21] The large absorptive surface area, highly permeable membrane with rich blood supply also enable rapid onset of action and increase bioavailability of the drug. [21]

Disadvantages and challenges

Despite a number of advantages in the pulmonary route compared to other routes of administration, numerous disadvantages are associated with the pulmonary route. As the drug needs to be delivered through the respiratory tract to the lungs, drug formulation can be challenging due to the defense mechanisms which intend to remove or inactivate the exogenous chemicals. Airway constriction and mucus secretion with ciliary movement prevent drugs from reaching the lungs, while enzymes, macrophages and surfactant in the lungs may also inactivate the drugs leading to less drug being absorbed. [2] Studies show that only around 20% of drug reaches the lung for each inhalation and drug loss is mainly due to the accumulation in the oropharynx in terms of pMDIs and DPIs and drug retention in the device for nebulisers. [2]

Some irritating drug particles may also cause local side effects at the respiratory tract, for example inhaled corticosteroid accumulating in the oropharynx can result in dysphonia and oral thrush. Besides, drug dosing may be inaccurate due to the variations of breathing patterns between individuals and the presence of numerous factors affecting the deposition and absorption of drug particles in the lungs. [20] In particular, elder patients may not have enough strength to generate sufficient inspiratory flow, resulting in less drug inhalation and hence low drug bioavailability. Finally, inhalers, especially nebulizers, require regular maintenance and cleaning. The inhaler devices are relatively expensive compared to oral tablets, [22] which may not be affordable to low income patients.

The effectiveness of drug delivery highly depends on the patient's compliance and proper inhaler technique with no significant error in using the inhalers. Poor compliance may lead to uncontrolled or poorly controlled disease status. [23] For instance, a patient may feel recovered and discontinue the treatment, or a patient may forget to take the medication, resulting in suboptimal disease management. Reducing the amount of puffs by combination inhalers delivering two or more drugs in one breath or the use of electronic data loggers can improve compliance. [23]

Incorrect inhaler techniques, such as poor coordination, no exhalation before inhaling the drug aerosol or not holding breath for a few seconds after inhalation may lead to medication depositing inside the respiratory tract instead of the lungs, resulting in inefficient and inadequate treatment. [23] [24] Practical demonstration instead of verbal instruction, education and rechecking on the inhaler technique after a period of time can reduce error and enhance true compliance.

Ongoing development

The use of the pulmonary route as an entry into the systemic circulation is constantly developing due to the additional benefits of bypassing the hepatic first pass metabolism, rapid systemic absorption, higher patients compliance and its non-invasive nature. Potent drugs with the ability to penetrate the lung mucosa into the blood circulation may be available for treating diseases requiring systemic drug delivery. [25] The ongoing researches include the use of inhaled nicotine for smoking cessation, [26] the use of inhaled levodopa for the treatment of Parkinson's disease, [27] and the pulmonary delivery of various biologics. [28]

In addition to the development of new pulmonary drugs, the drug formulation and particle engineering technology is advancing, such as the use of Ultrasound Mediated Amorphous to Crystalline transition (UMAX) process to micronize drug into inhalable drug particles with better performance, [29] the use of drug nanoparticles to minimize unwanted drug adverse effects and increase drug bioavailability at the target site, [30] and the use of porous drug particles to improve pulmonary delivery efficacy. [31]

See also

Related Research Articles

<span class="mw-page-title-main">Inhaler spacer</span>

A spacer is a device used to increase the ease of administering aerosolized medication from a metered-dose inhaler (MDI). It adds space in the form of a tube or "chamber" between the mouth and canister of medication. Most spacers have a one-way valve that allows the person to inhale the medication while inhaling and exhaling normally; these are often referred to as valved holding chambers (VHC).

<span class="mw-page-title-main">Route of administration</span> Path by which a drug, fluid, poison, or other substance is taken into the body

A route of administration in pharmacology and toxicology is the way by which a drug, fluid, poison, or other substance is taken into the body.

<span class="mw-page-title-main">Salbutamol</span> Medication

Salbutamol, also known as albuterol and sold under the brand name Ventolin among others, is a medication that opens up the medium and large airways in the lungs. It is a short-acting β2 adrenergic receptor agonist which works by causing relaxation of airway smooth muscle. It is used to treat asthma, including asthma attacks, exercise-induced bronchoconstriction, and chronic obstructive pulmonary disease (COPD). It may also be used to treat high blood potassium levels. Salbutamol is usually used with an inhaler or nebulizer, but it is also available in a pill, liquid, and intravenous solution. Onset of action of the inhaled version is typically within 15 minutes and lasts for two to six hours.

<span class="mw-page-title-main">Oxygen therapy</span> Use of oxygen as a medical treatment

Oxygen therapy, also known as supplemental oxygen, is the use of oxygen as medical treatment. Acute indications for therapy include hypoxemia, carbon monoxide toxicity and cluster headache. It may also be prophylactically given to maintain blood oxygen levels during the induction of anesthesia. Oxygen therapy is often useful in chronic hypoxemia caused by conditions such as severe COPD or cystic fibrosis. Oxygen can be delivered via nasal cannula or face mask, or via high pressure conditions such as in endotracheal intubation or hyperbaric chamber. It can also be given through bypassing the airway, such as in ECMO therapy.

<span class="mw-page-title-main">Nebulizer</span> Drug delivery device

In medicine, a nebulizer or nebuliser is a drug delivery device used to administer medication in the form of a mist inhaled into the lungs. Nebulizers are commonly used for the treatment of asthma, cystic fibrosis, COPD and other respiratory diseases or disorders. They use oxygen, compressed air or ultrasonic power to break up solutions and suspensions into small aerosol droplets that are inhaled from the mouthpiece of the device. An aerosol is a mixture of gas and solid or liquid particles.

<span class="mw-page-title-main">Ipratropium bromide</span> Type of anticholinergic

Ipratropium bromide, sold under the trade name Atrovent among others, is a type of anticholinergic medication which opens up the medium and large airways in the lungs. It is used to treat the symptoms of chronic obstructive pulmonary disease and asthma. It is used by inhaler or nebulizer. Onset of action is typically within 15 to 30 minutes and lasts for three to five hours.

Alcohol inhalation is a method of administering alcohol directly into the respiratory system, with aid of a vaporizing or nebulizing device. It is chiefly applied for recreational use, when it is also referred to as alcohol smoking, but it has medical applications for testing on laboratory rats, and treatment of pulmonary edema and viral pneumonia. Depending on precise definition of alcohol, botanical alcohol inhalation can be a subgenre of aromatherapy.

<span class="mw-page-title-main">Inhaler</span> Medical device

An inhaler is a medical device used for delivering medicines into the lungs through the work of a person's breathing. This allows medicines to be delivered to and absorbed in the lungs, which provides the ability for targeted medical treatment to this specific region of the body, as well as a reduction in the side effects of oral medications. There are a wide variety of inhalers, and they are commonly used to treat numerous medical conditions with asthma and chronic obstructive pulmonary disease (COPD) being among the most notable.

Beta<sub>2</sub>-adrenergic agonist Compounds that bind to and activate adrenergic beta-2 receptors

Beta2-adrenergic agonists, also known as adrenergic β2 receptor agonists, are a class of drugs that act on the β2 adrenergic receptor. Like other β adrenergic agonists, they cause smooth muscle relaxation. β2 adrenergic agonists' effects on smooth muscle cause dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin. They are primarily used to treat asthma and other pulmonary disorders, such as Chronic obstructive pulmonary disease (COPD).

<span class="mw-page-title-main">Metered-dose inhaler</span>

A metered-dose inhaler (MDI) is a device that delivers a specific amount of medication to the lungs, in the form of a short burst of aerosolized medicine that is usually self-administered by the patient via inhalation. It is the most commonly used delivery system for treating asthma, chronic obstructive pulmonary disease (COPD) and other respiratory diseases. The medication in a metered dose inhaler is most commonly a bronchodilator, corticosteroid or a combination of both for the treatment of asthma and COPD. Other medications less commonly used but also administered by MDI are mast cell stabilizers, such as cromoglicate or nedocromil.

<span class="mw-page-title-main">Iloprost</span>

Iloprost is a medication used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon and other diseases in which the blood vessels are constricted and blood cannot flow to the tissues. This damages the tissues and causes high blood pressure. There is ongoing research into using it as a frostbite treatment. Iloprost works by opening (dilating) the blood vessels to allow the blood to flow through again. It was developed by the pharmaceutical company Schering AG and is marketed by Bayer Schering Pharma AG in Europe and Actelion Pharmaceuticals in the USA. Iloprost is given via inhalation, and a therapeautic benefit of the drug is that a very low dose is required because of the deposition in the lung. Iloprost has few systemic side effects for that reason.

<span class="mw-page-title-main">Smoke inhalation</span> Medical condition

Smoke inhalation is the breathing in of harmful fumes through the respiratory tract. This can cause smoke inhalation injury which is damage to the respiratory tract caused by chemical and/or heat exposure as well as possible systemic toxicity after smoke inhalation. Smoke inhalation can occur from fires of various sources such as residential, vehicle, and wildfires. Morbidity and mortality rates in fire victims with burns are increased in those with smoke inhalation injury. Victims of smoke inhalation injury can present with cough, difficulty breathing, low oxygen saturation, smoke debris and/or burns on the face. Smoke inhalation injury can affect the upper respiratory tract, usually due to heat exposure, or the lower respiratory tract, usually due to exposure to toxic fumes. Initial treatment includes taking the victim away from the fire and smoke, give 100% oxygen at high flow through face mask, and check the victim for injuries to the body. Treatment for smoke inhalation injury is largely supportive with varying degrees of consensus on benefits of specific treatments.

<span class="mw-page-title-main">Dry-powder inhaler</span>

A dry-powder inhaler (DPI) is a device that delivers medication to the lungs in the form of a dry powder. DPIs are commonly used to treat respiratory diseases such as asthma, bronchitis, emphysema and COPD although DPIs have also been used in the treatment of diabetes mellitus.

<span class="mw-page-title-main">David Edwards (engineer)</span> American biomedical engineer

David A. Edwards is an American biomedical engineer, and the founder of Sensory Cloud. He was the Gordon McKay Professor of the Practice of Biomedical Engineering at Harvard University.

Ciclosporin is a cyclic polypeptide that has been used widely as an orally-available immunosuppressant. It was originally used to prevent transplant rejection of solid organs but has also found use as an orally administered agent to treat psoriasis, rheumatoid arthritis, dry eye and other auto-immune related conditions. A variety of pre-clinical and clinical studies have been and are investigating its use to treat lung-related disorders via inhalation.

<span class="mw-page-title-main">Acute exacerbation of chronic obstructive pulmonary disease</span> Medical condition

An acute exacerbation of chronic obstructive pulmonary disease, or acute exacerbations of chronic bronchitis (AECB), is a sudden worsening of chronic obstructive pulmonary disease (COPD) symptoms including shortness of breath, quantity and color of phlegm that typically lasts for several days.

<span class="mw-page-title-main">Tiotropium bromide</span> Long-acting bronchodilator in the maintenance of COPD and asthma

Tiotropium bromide, sold under the brand name Spiriva among others, is a long-acting bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Specifically it is used during periods of breathing difficulty to prevent them from getting worse, rather than to prevent them from happening. It is used by inhalation through the mouth. Onset typically begins within half an hour and lasts for 24 hours.

<span class="mw-page-title-main">Budesonide</span> Type of corticosteroid medication; group of stereoisomers

Budesonide, sold under the brand name Pulmicort among others, is a medication of the corticosteroid type. It is available as an inhaler, nebulization solution, pill, nasal spray, and rectal forms. The inhaled form is used in the long-term management of asthma and chronic obstructive pulmonary disease (COPD). The nasal spray is used for allergic rhinitis and nasal polyps. The pills in a delayed release form and rectal forms may be used for inflammatory bowel disease including Crohn's disease, ulcerative colitis, and microscopic colitis.

Intratracheal instillation is the introduction of a substance directly into the trachea. It is widely used to test the respiratory toxicity of a substance as an alternative to inhalation in animal testing. Intratracheal instillation was reported as early as 1923 in studies of the carcinogenicity of coal tar. Modern methodology was developed by several research groups in the 1970s. By contrast, tracheal administration of pharmaceutical drugs in humans is called endotracheal administration.

Fluticasone furoate/umeclidinium bromide/vilanterol, sold under the brand name Trelegy Ellipta among others, is a fixed-dose combination inhaled medication that is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The medications work in different ways: fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta-agonist (LABA).

References

  1. ↑ Liang, Wanling; Pan, Harry W.; Vllasaliu, Driton; Lam, Jenny K. W. (2020-10-26). "Pulmonary Delivery of Biological Drugs". Pharmaceutics. 12 (11): 1025. doi: 10.3390/pharmaceutics12111025 . ISSN   1999-4923. PMC   7693150 . PMID   33114726.
  2. 1 2 3 Newman, Stephen P (2017). "Drug delivery to the lungs: challenges and opportunities". Therapeutic Delivery. 8 (8): 647–661. doi:10.4155/tde-2017-0037. ISSN   2041-5990. PMID   28730933.
  3. ↑ Chan, Jason; Cheng-Lai, Angela (2017). "Inhaled Insulin: A Clinical and Historical Review". Cardiology in Review. 25 (3): 140–146. doi:10.1097/CRD.0000000000000143. ISSN   1061-5377. PMID   28379903. S2CID   22883456.
  4. ↑ Cataldo, Didier; Hanon, Shane; Peché, Rudi V.; Schuermans, Daniel J.; Degryse, Jean M.; De Wulf, Isabelle A.; Elinck, Karin; Leys, Mathias H.; Rummens, Peter L.; Derom, Eric (2022). "How to Choose the Right Inhaler Using a Patient-Centric Approach?". Advances in Therapy. 39 (3): 1149–1163. doi:10.1007/s12325-021-02034-9. ISSN   0741-238X. PMC   8790222 . PMID   35080761.
  5. ↑ Roncada, Cristian; Andrade, Julia; Bischoff, Luísa Carolina; Pitrez, Paulo Márcio (2018-07-10). "COMPARAÇÃO DE DUAS TÉCNICAS INALATÓRIAS PARA ADMINISTRAR BRONCODILATADOR EM CRIANÇAS E ADOLESCENTES COM CRISE AGUDA DE ASMA: METANÁLISE". Revista Paulista de Pediatria. 36 (3): 364–371. doi:10.1590/1984-0462/;2018;36;3;00002. ISSN   1984-0462. PMC   6202895 . PMID   29995144.
  6. ↑ Volerman, Anna; Balachandran, Uma; Siros, Michelle; Akel, Mary; Press, Valerie G. (2021). "Mask Use with Spacers/Valved Holding Chambers and Metered Dose Inhalers among Children with Asthma". Annals of the American Thoracic Society. 18 (1): 17–22. doi:10.1513/AnnalsATS.202005-522CME. ISSN   2329-6933. PMC   7780969 . PMID   33052700.
  7. 1 2 3 4 Chandel, Akshay; Goyal, Amit K.; Ghosh, Goutam; Rath, Goutam (2019). "Recent advances in aerosolised drug delivery". Biomedicine & Pharmacotherapy. 112: 108601. doi: 10.1016/j.biopha.2019.108601 . PMID   30780107. S2CID   73456189.
  8. ↑ Lavorini, Federico; Chudek, Jerzy; Gálffy, Gabriella; Pallarés-Sanmartin, Abel; Pelkonen, Anna S.; Rytilä, Paula; Syk, Jörgen; Szilasi, Maria; Tamási, Lilla; Xanthopoulos, Athanasios; Haahtela, Tari (2021-12-01). "Switching to the Dry-Powder Inhaler Easyhaler®: A Narrative Review of the Evidence". Pulmonary Therapy. 7 (2): 409–427. doi:10.1007/s41030-021-00174-5. ISSN   2364-1746. PMC   8477976 . PMID   34581994.
  9. ↑ Ghosh, Sohini; Ohar, Jill A.; Drummond, M. Bradley (2017). "Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers". Journal of Aerosol Medicine and Pulmonary Drug Delivery. 30 (6): 381–387. doi:10.1089/jamp.2017.1416. ISSN   1941-2711. PMC   5915227 . PMID   28933581.
  10. 1 2 3 ElKasabgy, Nermeen A.; Adel, Islam M.; Elmeligy, Mohamed F. (2020-08-21). "Respiratory Tract: Structure and Attractions for Drug Delivery Using Dry Powder Inhalers". AAPS PharmSciTech. 21 (7): 238. doi:10.1208/s12249-020-01757-2. ISSN   1530-9932. PMID   32827062. S2CID   221218042.
  11. ↑ Iwanaga, Takashi; Tohda, Yuji; Nakamura, Shuhei; Suga, Yasunori (2019-11-01). "The Respimat® Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients". Clinical Drug Investigation. 39 (11): 1021–1030. doi:10.1007/s40261-019-00835-z. ISSN   1179-1918. PMC   6800401 . PMID   31377981.
  12. ↑ Wachtel, Herbert; Kattenbeck, Sabine; Dunne, Stephen; Disse, Bernd (2017). "The Respimat® Development Story: Patient-Centered Innovation". Pulmonary Therapy. 3 (1): 19–30. doi: 10.1007/s41030-017-0040-8 . ISSN   2364-1754. S2CID   51800400.
  13. ↑ Sorino, Claudio; Negri, Stefano; Spanevello, Antonio; Visca, Dina; Scichilone, Nicola (2020-05-01). "Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler". European Journal of Internal Medicine. 75: 15–18. doi:10.1016/j.ejim.2020.02.023. ISSN   0953-6205. PMID   32113944. S2CID   211727980.
  14. ↑ Longest, Worth; Spence, Benjamin; Hindle, Michael (2019-10-01). "Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs". Journal of Aerosol Medicine and Pulmonary Drug Delivery. 32 (5): 317–339. doi:10.1089/jamp.2018.1508. ISSN   1941-2711. PMC   6781258 . PMID   31287369.
  15. ↑ McCarthy, Sean D.; González, Héctor E.; Higgins, Brendan D. (2020). "Future Trends in Nebulized Therapies for Pulmonary Disease". Journal of Personalized Medicine. 10 (2): 37. doi: 10.3390/jpm10020037 . ISSN   2075-4426. PMC   7354528 . PMID   32397615.
  16. 1 2 Khairnar, Sakshi V; Jain, Divya D; Tambe, Srushti M; Chavan, Yashashri R; Amin, Purnima D (2022). "Nebulizer systems: a new frontier for therapeutics and targeted delivery". Therapeutic Delivery. 13 (1): 31–49. doi:10.4155/tde-2021-0070. ISSN   2041-5990. PMID   34766509. S2CID   244041247.
  17. ↑ Martin, Andrew R.; Moore, Charles P.; Finlay, Warren H. (2018-12-02). "Models of deposition, pharmacokinetics, and intersubject variability in respiratory drug delivery". Expert Opinion on Drug Delivery. 15 (12): 1175–1188. doi:10.1080/17425247.2018.1544616. ISSN   1742-5247. PMID   30388902. S2CID   53266146.
  18. ↑ Darquenne, Chantal (2020-08-01). "Deposition Mechanisms". Journal of Aerosol Medicine and Pulmonary Drug Delivery. 33 (4): 181–185. doi:10.1089/jamp.2020.29029.cd. ISSN   1941-2711. PMID   32598200. S2CID   220275931.
  19. ↑ Finlay, Warren H. (2021-08-01). "Deposition of Aerosols in the Lungs: Particle Characteristics". Journal of Aerosol Medicine and Pulmonary Drug Delivery. 34 (4): 213–216. doi:10.1089/jamp.2021.29040.whf. ISSN   1941-2711. PMID   34264776. S2CID   235959447.
  20. 1 2 3 Rangaraj, Nagarjun; Pailla, Sravanthi Reddy; Sampathi, Sunitha (2019). "Insight into pulmonary drug delivery: Mechanism of drug deposition to device characterization and regulatory requirements". Pulmonary Pharmacology & Therapeutics. 54: 1–21. doi:10.1016/j.pupt.2018.11.004. PMID   30447295. S2CID   53670288.
  21. 1 2 3 Labiris, N. R.; Dolovich, M. B. (2003). "Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications: Physiological factors affecting the effectiveness of inhaled drugs". British Journal of Clinical Pharmacology. 56 (6): 588–599. doi:10.1046/j.1365-2125.2003.01892.x. PMC   1884307 . PMID   14616418.
  22. ↑ Khan, Muhammad Suleman; Roberts, Michael S. (2018). "Challenges and innovations of drug delivery in older age". Advanced Drug Delivery Reviews. 135: 3–38. doi:10.1016/j.addr.2018.09.003. PMID   30217519. S2CID   52276293.
  23. 1 2 3 Chrystyn, Henry; van der Palen, Job; Sharma, Raj; Barnes, Neil; Delafont, Bruno; Mahajan, Anadi; Thomas, Mike (2017). "Device errors in asthma and COPD: systematic literature review and meta-analysis". NPJ Primary Care Respiratory Medicine. 27 (1): 22. doi:10.1038/s41533-017-0016-z. ISSN   2055-1010. PMC   5434773 . PMID   28373682.
  24. ↑ Melani, Andrea S. (2021). "Inhaler technique in asthma and COPD: challenges and unmet knowledge that can contribute to suboptimal use in real life". Expert Review of Clinical Pharmacology. 14 (8): 991–1003. doi:10.1080/17512433.2021.1929922. ISSN   1751-2433. PMID   33983092. S2CID   234486685.
  25. ↑ Hickey, Anthony J. (2020). "Emerging trends in inhaled drug delivery". Advanced Drug Delivery Reviews. 157: 63–70. doi:10.1016/j.addr.2020.07.006. PMC   7354278 . PMID   32663488.
  26. ↑ Jackson, Asti; Grobman, Ben; Krishnan-Sarin, Suchitra (2020). "Recent findings in the pharmacology of inhaled nicotine: Preclinical and clinical in vivo studies". Neuropharmacology. 176: 108218. doi:10.1016/j.neuropharm.2020.108218. PMC   7529934 . PMID   32592708.
  27. ↑ Paik, Julia (2020). "Levodopa Inhalation Powder: A Review in Parkinson's Disease". Drugs. 80 (8): 821–828. doi:10.1007/s40265-020-01307-x. ISSN   0012-6667. PMID   32319076. S2CID   216033034.
  28. ↑ Anselmo, Aaron C.; Gokarn, Yatin; Mitragotri, Samir (2019). "Non-invasive delivery strategies for biologics". Nature Reviews Drug Discovery. 18 (1): 19–40. doi:10.1038/nrd.2018.183. ISSN   1474-1776. PMID   30498202. S2CID   54166853.
  29. ↑ Biddiscombe, Martyn F.; Usmani, Omar S. (2018). "Is there room for further innovation in inhaled therapy for airways disease?". Breathe. 14 (3): 216–224. doi:10.1183/20734735.020318. ISSN   1810-6838. PMC   6118889 . PMID   30186519.
  30. ↑ García-Fernández, Alba; Sancenón, Félix; Martínez-Máñez, Ramón (2021). "Mesoporous silica nanoparticles for pulmonary drug delivery". Advanced Drug Delivery Reviews. 177: 113953. doi:10.1016/j.addr.2021.113953. PMID   34474094.
  31. ↑ Duong, Thoa; López-Iglesias, Clara; Szewczyk, Piotr K.; Stachewicz, Urszula; Barros, Joana; Alvarez-Lorenzo, Carmen; Alnaief, Mohammad; García-González, Carlos A. (2021-05-04). "A Pathway From Porous Particle Technology Toward Tailoring Aerogels for Pulmonary Drug Administration". Frontiers in Bioengineering and Biotechnology. 9: 671381. doi: 10.3389/fbioe.2021.671381 . ISSN   2296-4185. PMC   8129550 . PMID   34017828.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.